Risk Stratification in ccRCC: The Impact in Patient Populations

Molecular Imaging in Risk Stratification and Adjuvant Therapy

Main Discussion Topics:

• Potential role in identifying patients appropriate for adjuvant pembrolizumab after nephrectomy
• Possible utility for improving detection of occult metastatic disease
• Could help identify patients needing more intensive therapy beyond single-agent approaches
• May also identify patients who could be spared morbidity of unnecessary treatment

Key Points for Physicians:

• Molecular imaging could identify occult metastatic disease missed by conventional imaging.
• Patients with positive findings outside the primary tumor may benefit from combination therapy rather than single-agent therapy.
• Patients with negative scans might be candidates for de-escalation of therapy.
• Represents a significant opportunity for clinical trials and personalized approaches.

Notable Insights:

Similar to the evolution in prostate cancer management, molecular imaging in RCC may fundamentally change staging and treatment intensity decisions.

Clinical Significance:

This technology could help tailor treatment intensity, potentially intensifying therapy for those with occult metastatic disease while sparing others from unnecessary treatment.